Edesa Biotech Receives FDA Clearance for Phase 2 Vitiligo Study
The FDA cleared the investigational new drug application for Edesa Biotech’s Phase 2 vitiligo study.
Story updates
01:17:08 PM UTC
SquawkNews
Edesa Biotech, Inc. received FDA IND clearance for its Phase 2 study of EB06 in vitiligo, enabling U.S. site enrollment next quarter. Recruitment is underway in Canada; topline data are anticipated in Q4 2027.Material DetailsContext by AI AnalystThis is an early-to-mid development milestone expandi…